CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 374 enrolled
Drug / intervention
Tolterodine tartratedrug
Likely dose
Tolterodine tartrate 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00795509
NCT00795509N/ACompleted
CompareCT.gov

Special Investigation For Long Term Use Of Detrusitol (Regulatory Post Marketing Commitment Plan).

Pfizer·observational·Posted Nov 21, 2008·Updated Jul 9, 2012

In Brief

An observational study evaluating Tolterodine tartrate for Urinary Bladder, Overactive. Completed, enrolled 374 participants.

Detailed Summary

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Bladder, Overactive
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 21, 2008
Enrollment StartAug 1, 2007
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 17.6 years ago

Interventions

Tolterodine tartratedrug

Detrusitol® Capsule 2mg and 4mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. " The usual adult dosage for oral administration is 4 mg of tolterodine tartrate once daily. Occasionally dose reduction might be needed due to individual tolerability."